Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression, according to the results of a phase I study conducted by researchers at Mass General Cancer Center.
Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.
